

# PRECISION ADVANCE the cell & gene therapy collective™

PRECISION  
for medicine

PROJECT FARMA

PRECISION  
value & health

## Precision ADVANCE Expertise

### Thought Leadership



- [Breaking The Bottleneck For Cell And Gene Therapy Studies: Strategies For Creating Clinical Enthusiasm And Selecting Sites](#)

*Cell & Gene, January, 2021.*



- [Manufacturing Skills Gap Creates Bottleneck for Cell and Gene Therapy](#)

*BioSpace, February, 2021.*




- [How To Calculate Viral Vector Yields: A Critical Component Of The "Make vs Buy" Analysis](#)

*Cell & Gene, March, 2021.*




- [Taking On The Talent Crunch In Biopharma, Cell & Gene Manufacturing](#)

*Cell & Gene, March, 2021.*



- [Cell and Gene Therapy: The Impact of Skills Gaps in a Fast-Growing Sector](#)

*Pharmaceutical Technology, April, 2021.*



- [Payers Create CAR-T Approval Systems as Adoption Increases](#)

*AIS Health, June, 2021.*

---

## Peer-Reviewed Papers and Posters



- Costs and Health Resource Use in Patients with X-Linked Myotubular Myopathy: Insights from U.S. Commercial Claims. Journal of Managed Care & Specialty Pharmacy. 2021.

*Precision Value & Health: Naomi Sacks, Bridget Healey, Phil Cyr, Emma James, Alan Beggs, Robert Graham*



- An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER). Journal of Market Access & Health Policy. 2020.

*Precision Value & Health: Phil Cyr, Rebecca Dean, Ivar Jensen, Beckley Miller*




- Healthcare resource use and expenditures in patients with X-linked myotubular myopathy (XLMTM). ISPOR 25th Annual International Meeting. Orlando FL. 2020.

*Precision Value & Health: Phil Cyr*



- Economic Burden of X-Linked Myotubular Myopathy (XLMTM) By Ventilation Status. ISPOR 25th Annual International Meeting. Orlando FL. 2020.

*Precision Value & Health: Naomi Sacks, Bridget Healey, Phil Cyr, Emma James, Alan Beggs, Robert Graham*



- Recommendations for the Development of Cell-Based Anti-Viral Vector Neutralizing Antibody Assays. AAPS Journal. 2020.

*Precision for Medicine: Eugen Koren*

---

## White Papers



- Advantages of Using POD Cleanroom Technology

*Project Farma*



- Optimizing Successful Development of Viral Vector Gene Therapies, Gene Therapy Trials, and Companion Diagnostics

*Precision for Medicine*



- Delivering on the Promise of Cell Therapy: Challenges and Trends

*Precision for Medicine*



- Perspectives on Gene Therapy: Defining and Demonstrating Value to Payers

*Precision Value & Health*



- Developing Advanced Therapies: Considerations for Internal Versus External Manufacturing

*Project Farma*



- What to Consider When Conducting a “Make vs. Buy” Analysis for a Cell & Gene Therapy Facility

*Project Farma*

---

**Connect with one of our experts.**

Contact us at [precisionadvance@precisionmedicinegrp.com](mailto:precisionadvance@precisionmedicinegrp.com).

PRECISION the cell &  
**ADVANCE** gene therapy  
collective™

---

To learn more about Precision ADVANCE, visit [precisionmedicinegrp.com/advance](https://precisionmedicinegrp.com/advance).